Zoetis Inc. (NYSE:ZTS) Shares Bought by Tidal Investments LLC

Tidal Investments LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 22.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,668 shares of the company's stock after purchasing an additional 3,458 shares during the quarter. Tidal Investments LLC's holdings in Zoetis were worth $3,042,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in shares of Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock worth $569,834,000 after buying an additional 279,092 shares during the period. Merit Financial Group LLC raised its position in shares of Zoetis by 19.4% in the 4th quarter. Merit Financial Group LLC now owns 7,502 shares of the company's stock worth $1,222,000 after buying an additional 1,219 shares during the period. Ballentine Partners LLC raised its position in shares of Zoetis by 3.0% in the 4th quarter. Ballentine Partners LLC now owns 12,151 shares of the company's stock worth $1,980,000 after buying an additional 357 shares during the period. Crossmark Global Holdings Inc. raised its position in shares of Zoetis by 13.0% in the 4th quarter. Crossmark Global Holdings Inc. now owns 36,936 shares of the company's stock worth $6,018,000 after buying an additional 4,248 shares during the period. Finally, Atomi Financial Group Inc. raised its position in shares of Zoetis by 10.4% in the 4th quarter. Atomi Financial Group Inc. now owns 6,651 shares of the company's stock worth $1,084,000 after buying an additional 626 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ZTS shares. Piper Sandler increased their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Finally, Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average price target of $212.75.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Zoetis Stock Up 0.6%

Shares of NYSE ZTS traded up $0.95 during midday trading on Friday, reaching $162.92. 2,732,205 shares of the company's stock were exchanged, compared to its average volume of 2,528,663. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market capitalization of $72.53 billion, a PE ratio of 29.78, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business's fifty day moving average price is $156.48 and its two-hundred day moving average price is $164.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period in the previous year, the company earned $1.38 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis's dividend payout ratio (DPR) is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.